CN105943544A - Medicine composition for treating migraine - Google Patents
Medicine composition for treating migraine Download PDFInfo
- Publication number
- CN105943544A CN105943544A CN201610010466.9A CN201610010466A CN105943544A CN 105943544 A CN105943544 A CN 105943544A CN 201610010466 A CN201610010466 A CN 201610010466A CN 105943544 A CN105943544 A CN 105943544A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- medicine composition
- migraine
- combination
- successively
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a medicine composition for treating migraine. The medicine composition includes topiramate, at least one another anti-epileptic drug, and at least one optionally pharmaceutically acceptable carrier, wherein the active components in the medicine composition exist in a freeing form or in the form of a pharmaceutically acceptable salt under any situation. The composition is applied simultaneously, separately or successively. Preferably, the anti-epileptic drug is tetrahydropalmatine. The medicine composition, according to the medicines in different action mechanisms, fully achieves the complementary and synergistic effects, and reduces the adverse reactions related to increase of dosage of one component. The medicine composition can relieve the symptoms in a short period and can effectively treat the migraine.
Description
Technical field
The present invention relates to pharmaceutical technology field, be specifically related to one and treat migrainous pharmaceutical composition and application thereof.
Background technology
Migraine is a kind of pulsation headache of recurrent exerbation, it it is a kind of commonly encountered diseases, the tendencys such as flash of light, blurred vision, numb limbs and tense tendons are often had before outbreak, there is, to about 1 hour, the pain that side head one is jumped in few minutes, and gradually aggravate, until after there is Nausea and vomiting, sensation just has and taken a turn for the better, in peace and quiet, dark surrounds or after sleep, headache is alleviated.Can be with neural, mental function disorder before headache occurs or when showing effect.Meanwhile, it is a kind of disease that can progressively deteriorate, and frequency of disease development is more and more higher.Showing according to the study, migraine patient people than usual is easier to occur brain local damage, and then causes apoplexy.The number of times of its migraine is the most, and the region of brain damage wound can be the biggest.Migraine can betide any age bracket, is more common between 35-45 year and peaks, and afterwards, migrainous incidence rate is gradually reduced with advancing age.The most fully aware of to migrainous pathogeny and pathological molecule mechanism.Although prior art also having for treating migrainous medicine, but the therapeutic effect of drug alone being difficult to meet the requirement of patient, so, the exploitation migrainous pharmaceutical composition of a kind of effective treatment is significant to play synergistic therapeutic effect.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, by drug screening and the clinical verification repeatedly of several years, it is provided that one treats migrainous pharmaceutical composition, and its feature is easy to use, can effectively treat migraine.In order to realize the purpose of the present invention, intend adopting the following technical scheme that
One aspect of the present invention relates to one and treats migrainous pharmaceutical composition, wherein comprise topiramate and at least one additional antiepileptic and optional at least one pharmaceutically useful carrier, active component therein is the most in a free form or presented in officinal salt, described combination is used for simultaneously, uses respectively or successively；Preferably, described antiepileptic is tetrahydropalmatine.
In a preferred embodiment of the present invention, described pharmaceutical composition is combination formulations or pharmaceutical composition, it is preferred that described topiramate is 2-4:1 with the weight proportion with another antiepileptic.
In a preferred embodiment of the present invention, described pharmaceutical composition is used for simultaneously, uses respectively or successively with prevention, delay of progression or treatment migraine.
The pharmaceutical composition of the present invention, its topiramate comprising treatment epilepsy effective dose and tetrahydropalmatine (weight proportion is 2-4:1) are as active constituents of medicine and at least one pharmaceutically useful carrier.
The invention still further relates to aforementioned pharmaceutical compositions in preparation for preventing, delay of progression or treat the purposes in migrainous medicine.
Another aspect of the present invention further relates to a kind of commercial packing, and it comprises power aforementioned pharmaceutical compositions, and is used in prevention, delay of progression or treatment migraine simultaneously, the operation instructions used respectively or successively.
Term " the associating agent be used for simultaneously, used respectively or successively or pharmaceutical composition " especially refers to one " component bag ", the meaning is components topiramate and tetrahydropalmatine can be used independently of one another or be used by the different fixed Combination with different component content, i.e. in different time points or uses simultaneously.So, the component of component bag can be used the most simultaneously or interval is used in chronological order, i.e. in different time points and any component of using component bag with identical or different time interval.Preferably, selected time interval should make component effect to treated disease or disease to be used in combination higher than only using any obtained effect of single component.
Term " prevents " to refer to prophylactically use described combination to healthy patients to prevent disease described herein and disease from occurring.Additionally, term " prevents ", the patient that may point to be in disease early stage to be treated is preventative uses described combination.Term used herein " delay of progression " refers to prophylactically use described combination to the patient of the front disease being in disease early stage to be treated, being diagnosed with corresponding disease.
In the present invention combination of therapeutically effective amount, every kind of component can or use with any successively simultaneously, and described component can be used respectively or use as fixed Combination.Single component in combination can be used or with separate or single combining form and use respectively at the different time during treating.Additionally, term administering " also include that use can be converted into the prodrug of any medicine of selected medicine in vivo.Therefore, should invention is construed as including all these scheme either simultaneously or alternately treated, and should be correspondingly to term administering " explain.
The preferred route of administration of dosage form of the present invention is through enteral or preferred oral approach.Owing to using the optimal oral dosage unit form of convenience, tablet and Capsules representative, in this case, it is evident that solid pharmaceutical carriers need to be used.
The effective dose of every kind of active component used in therapeutic alliance can change with the concrete pharmaceutical composition used, occupation mode or the sanatory order of severity of institute.
It is an advantage of the invention that the medicine according to the different mechanism of action of combination, give full play to medicine complementation synergism, and reduce the untoward reaction relevant to the increase of certain dose, take pharmaceutical composition of the present invention, can relief of symptoms at short notice, can effectively treat migraine.
Detailed description of the invention
If not specified, that technological means used in embodiment is well known to those skilled in the art conventional means.
Embodiment 1:
To illustrate that pharmaceutical composition of the present invention is to migrainous therapeutical effect by human body pharmacodynamic experiment below.
1, physical data:
In clinical 60 example migraine patients, age 20--35 year, 20 examples；Age 35--50 year, 20 examples, age 50--65 year, 20 examples.The course of disease of MethodsThe cases enrolled should at least one year, and clearer to the Headache attacks history of nearly 3 months.MethodsThe cases enrolled need to not use migrainous medicine at nearly 1 month, with the impact avoiding other drug to test this.The outbreak situation of MethodsThe cases enrolled should the most monthly be shown effect 2 times, the most monthly outbreak 2-6 time.
2, diagnostic criteria: according to [International Headache association (International
Headache Society, IHS) " the migraine diagnostic criteria " formulated.
3, Therapeutic Method: by 60 example migraine patients, uses randomized to be divided into 3 groups, and wherein negative control group takes placebo；Positive controls takes 200mg topiramate/sky；Experimental group takes 100 mg topiramate+30mg tetrahydropalmatines/sky.
4, efficacy assessment standard:
According to [International Headache association (International
Headache Society, IHS) " the migraine diagnostic criteria " formulated draft.Patient on medication treat latter 1 hour in headache disappear or in 2 hours the patient of headache relief be accordingly to be regarded as effectively.After 2 hours can not the person of alleviation be considered as invalid.
5, therapeutic outcome: headache severity when patient shows effect after treating with diary form record and pain relief degree in recording 2 hours after taking medicine, statistical result is as shown in the table:
Statistical result
| Group | N | Recovery from illness | Effectively | Invalid | Total effective rate |
| Experimental group | 20 | 8 | 10 | 2 | 90% |
| Positive controls | 20 | 6 | 8 | 6 | 70% |
| Negative control group | 20 | 0 | 2 | 18 | 10% |
As can be seen from the above table, the curative effect for the treatment of group patient is substantially better than the curative effect of matched group patient.
The above is the preferred embodiments of the present invention; it should be pointed out that, for those skilled in the art, on the premise of without departing from principle of the present invention; can also make some improvements and modifications, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (6)
1. treat migrainous pharmaceutical composition for one kind, wherein comprise topiramate and at least one additional antiepileptic and optional at least one pharmaceutically useful carrier, active component therein is the most in a free form or presented in officinal salt, described combination is used for simultaneously, uses respectively or successively；Preferably, described antiepileptic is tetrahydropalmatine.
2. the pharmaceutical composition described in claim 1, it is combination formulations or pharmaceutical composition, it is preferred that described topiramate is 2-4:1 with the weight proportion with another antiepileptic.
3. the pharmaceutical composition described in claim 1 or 2, it is used for simultaneously, uses respectively or successively with prevention, delay of progression or treatment migraine.
4. pharmaceutical composition, its combination of any one of claim 1 to 2 comprising treatment epilepsy effective dose and at least one pharmaceutically useful carrier.
5. the combination of any one of claim 1 to 2 in preparation for preventing, delay of progression or treat the purposes in migrainous medicine.
6. a commercial packing, it comprises the pharmaceutical composition described in claim 1 or 2, and in prevention, delay of progression or treatment migraine simultaneously, the operation instructions used respectively or successively.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610010466.9A CN105943544A (en) | 2016-01-08 | 2016-01-08 | Medicine composition for treating migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610010466.9A CN105943544A (en) | 2016-01-08 | 2016-01-08 | Medicine composition for treating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943544A true CN105943544A (en) | 2016-09-21 |
Family
ID=56917154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610010466.9A Pending CN105943544A (en) | 2016-01-08 | 2016-01-08 | Medicine composition for treating migraine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943544A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505734A (en) * | 2013-10-08 | 2014-01-15 | 湖南工业大学 | Composition containing r-aminobutyric acid and antiepileptic drugs |
-
2016
- 2016-01-08 CN CN201610010466.9A patent/CN105943544A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505734A (en) * | 2013-10-08 | 2014-01-15 | 湖南工业大学 | Composition containing r-aminobutyric acid and antiepileptic drugs |
Non-Patent Citations (2)
| Title |
|---|
| 张克义 主编: "《新编药物手册》", 31 October 1999, 辽宁科学技术出版社 * |
| 甘丽: "多巴胺能神经递质系统在癫痫发生与发展过程中的作用", 《武汉科技大学学报（自然科学版）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210030665A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| JP6313413B2 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| US11938123B2 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
| Chakradhar | Treatments that made headlines in 2018 | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN105943544A (en) | Medicine composition for treating migraine | |
| CN111821423B (en) | Application of interleukin 2 in treating chronic idiopathic urticaria | |
| CN116829135A (en) | Treatment of sleep apnea with cannabidiol | |
| González-Vílchez et al. | Conversion from immediate-release tacrolimus to prolonged-release tacrolimus in stable heart transplant patients: a retrospective study | |
| Hanaoka et al. | Efficacy of prophylactic intravenous granisetron in postoperative emesis in adults | |
| JP2008543730A (en) | Drugs and treatment for herpes simplex | |
| US20040192781A1 (en) | Method of administration for metoclopramide and pharmaceutical formulation therefor | |
| WO2013098049A1 (en) | Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate | |
| WO2010020789A2 (en) | Medicament and treatment for infections | |
| CN102552827B (en) | Medicine for treating epilepsy | |
| CN102008722A (en) | Compound preparation of naproxen and triptan drugs for treating migraine | |
| Khan et al. | The efficacy and safety of fixed dose sustained-release pregabalin, aceclofenic and methylcobalamin in sciatica and peripheral neuropathic pain | |
| CN103315989B (en) | A kind of pharmaceutical composition | |
| Takata et al. | Proposal for safe eradication therapy of Helicobacter pylori in patients with porphyria | |
| Gupta et al. | Role of Medications in Burning Mouth Syndrome: A Review | |
| US8680145B1 (en) | Compositions and methods for treatment of fear of medical procedures | |
| CN103301124B (en) | A kind of pharmaceutical composition for treating epilepsy | |
| Borges et al. | Study of a new analgesic compound in the treatment of tension headache | |
| CN106890217A (en) | A kind of Western medicine compound for treating dysmenorrhoea and its application | |
| CN102008723A (en) | Compound preparation of diclofenac sodium and triptan medicines for treating migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |
|
| RJ01 | Rejection of invention patent application after publication |